COVID-19 Statement

11 April 2020

Dear Valued Customers

As the COVID-19 pandemic continues to impact our communities, our hearts go out to anyone affected by the virus and we are especially grateful for the healthcare providers who are selflessly caring for the sick. We continue our longstanding mission to offer free stents to indigent patients or to patients who are impacted due to the COVID-19 pandemic on compassionate grounds.

Glaukos is focused on the health and safety of our workforce, customers, and patients. Relying on local orders and recommendations from federal and local government and health agencies, we have modified the way we work to protect the health and safety of our employees, customers and patients, while continuing to support our customers and their patients who depend on us.

In order to prioritize the needs of healthcare professionals, patients and its communities, while continuing to support its customers, Glaukos has acted quickly in recent weeks to implement several measures:

  • Maintaining Operations: Glaukos would like to assure you that we have adequate supply of inventory for both our glaucoma and corneal health products. Our customer service and operations teams continue to be available to fulfill and ship any product order requests. We stand ready to support your product needs whether during the COVID-19 pandemic or following when patients return to your practice.

  • Access to care: Glaukos also continues to maintain its longstanding mission to offer product donation and patient assistance programs for iStent, providing access to care for those who lack access to care or who lack insurance, including those who have lost insurance benefits due to the COVID-19 pandemic. As of late 2019, Glaukos has freely donated 5600 stents into 45 global countries and serviced 102 separate organizations that have come to us for help. Since its founding in 2001, Glaukos has yet to turn down a physician request for free stents for indigent patients or for altruistic mission trips.

Whether during or after this COVID-19 pandemic, our focus remains unchanged. Our focus is to develop and lead the global ophthalmic market with novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases—therapies that advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide.

We look forward to supporting you during these difficult times and will be ready to assist you and your patients’ needs.


Thomas W. Burns
President and CEO, Glaukos Corporation